As official media partners, VJHemOnc is thrilled to present updates from the 46th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT).
This year's meeting shed light on the latest research and education in hematological transplantation and cellular therapies.
In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?
Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021
How would you treat a fit patient with clonally related Richter Transformation (no active CLL) with systemic and parenchymal CNS involvement? #LymSM #lymphoma #iwCLL2021
Barbara Eichorst of @UKKoeln talks on the mechanisms and predictive markers of drug resistance in CLL at the #iwCLL2021 meeting 👩⚕️🔬 Watch now 👉http://ow.ly/DGxp50GbUlC👈 @VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia #HemOnc
Great talk on bispecific antibodies by Adrian Wiestner at the #iwCLL2021 meeting! 👨⚕️💉 Watch interviews with CLL experts here 👉http://ow.ly/vyi850GbSPz👈 @VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia
Explore all the practice-changing transplant updates presented at EBMT 2020 including conditioning, relapse risk factors and the impact of the microbiome!
CAR-T & Cellular Therapy
CAR-T has rapidly entered the treatment landscape of a vast number of hematological malignancies. Get the latest here!
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter